Vogelzang NJ, et al. - A retrospective claims investigation was carried out to evaluate real-world overall survival (OS), healthcare resource utilization (HRU), and healthcare costs (both all-cause and connected with renal cell carcinoma (RCC) diagnosis) among elderly advanced RCC patients starting pazopanib or sunitinib treatment. Among elderly Medicare patients with advanced RCC, first-line pazopanib treatment was related to significantly longer OS, and in addition lower healthcare costs and HRU, compared with first-line sunitinib treatment.